PepGen, Inc. (NASDAQ:PEPG) Receives Consensus Rating of “Moderate Buy” from Brokerages

PepGen, Inc. (NASDAQ:PEPG) has received an average recommendation of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.50.

A number of equities analysts have issued reports on PEPG shares. Wall Street Zen upgraded PepGen from a “sell” rating to a “hold” rating in a research note on Sunday, June 7th. Wedbush dropped their target price on PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Craig Hallum assumed coverage on PepGen in a research report on Tuesday, June 16th. They set a “buy” rating and a $11.00 target price on the stock. Weiss Ratings downgraded PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 2nd. Finally, HC Wainwright reissued a “buy” rating on shares of PepGen in a research report on Thursday, May 21st.

Institutional Trading of PepGen

Several institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC bought a new position in shares of PepGen during the first quarter valued at about $122,000. Woodline Partners LP purchased a new stake in PepGen in the 1st quarter valued at about $1,097,000. Marshall Wace LLP bought a new position in shares of PepGen during the 2nd quarter worth approximately $44,000. Qube Research & Technologies Ltd bought a new position in shares of PepGen in the second quarter valued at approximately $81,000. Finally, Bridgeway Capital Management LLC increased its position in shares of PepGen by 61.5% during the second quarter. Bridgeway Capital Management LLC now owns 91,923 shares of the company’s stock valued at $102,000 after acquiring an additional 35,000 shares during the last quarter. Institutional investors own 58.01% of the company’s stock.

PepGen Price Performance

Shares of NASDAQ PEPG opened at $2.99 on Friday. The company has a 50-day moving average price of $2.01 and a 200-day moving average price of $3.04. The stock has a market capitalization of $207.09 million, a P/E ratio of -2.28 and a beta of 1.89. PepGen has a 1 year low of $1.13 and a 1 year high of $7.80.

PepGen (NASDAQ:PEPG) last posted its earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. As a group, equities research analysts anticipate that PepGen will post -1.11 earnings per share for the current fiscal year.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).